Kuickresearch::Industry News

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 |

Advancing KIF18A: Therapeutic Insights and Innovations in Cancer Treatment

Release Date: 14 July 2024

KIF18A, a member of the kinesin superfamily of motor proteins, plays a crucial role in mitotic spindle dynamics and chromosome alignment during cell division. Its normal function involves the precise regulation of microtu...

Read More


Unlocking Cancer Treatment: The Power of Targeting Protein Disulfide Isomerase

Release Date: 14 July 2024

Protein disulfide isomerase (PDI), a multifunctional enzyme primarily located in the endoplasmic reticulum, plays a crucial role in protein folding, assembly, and quality control. Its normal functions include catalyzing the formation, reduction, and ...

Read More


PP2A: A Promising Target for Innovative Cancer Therapies

Release Date: 14 July 2024

PP2A, also known as protein phosphatase-2A, has shown great potential as a target for cancer treatment. By influencing important cellular signaling pathways that are crucial for tumor growth and survival, it offers a new ...

Read More


SFRP1: A Promising Target for Next-Generation Cancer Therapies

Release Date: 14 July 2024

Cancer is a complex and multifaceted disease that continues to pose significant challenges in the realm of drug development. One promising target that has gained attention in recent years is the secreted frizzled related ...

Read More


TL1A: A Key Target for Innovative Treatments in Autoimmune and Inflammatory Diseases

Release Date: 14 July 2024

Tumor necrosis factor (TNF)-like ligand 1a (TL1A) has emerged as a promising therapeutic target for autoimmune diseases and inflammatory conditions due to its critical role in regulating immune responses and inflammatory ...

Read More


Targeting SLC15A4: A New Frontier in Autoimmune and Inflammatory Disease Therapy

Release Date: 14 July 2024

SLC15A4, also known as the peptide/histidine transporter solute carrier family 15 member A4, has emerged as a promising therapeutic target in the realm of autoimmune diseases and inflammatory conditions due to its crucial...

Read More


Utilizing IL 21: Harnessing a Versatile Cytokine for Immune Therapy and Beyond

Release Date: 13 July 2024

Interleukin-21 (IL-21), a cytokine primarily produced by activated T cells and natural killer T cells, plays diverse roles in immune regulation, making it an attractive therapeutic target for various human diseases. Its m...

Read More


Breaking Barriers: Targeting HLA G to Revolutionize Cancer Immunotherapy

Release Date: 13 July 2024

Immune checkpoint-directed therapies have revolutionized cancer treatment by unleashing the body's immune system to combat tumors effectively. While agents targeting prominent checkpoints like PD-1/PD-L1 and CTLA-4 have s...

Read More


Harnessing FEN1 Inhibition for Cancer and Beyond

Release Date: 13 July 2024

Flap endonuclease 1 (FEN1) has emerged as a promising therapeutic target, particularly in the field of cancer research. This enzyme plays a crucial role in maintaining genomic stability by participating in various DNA rep...

Read More


DHX9: Uncovering Multifaceted Paths to Precision Medicine

Release Date: 13 July 2024

The DHX9 (DExH-Box Helicase 9) protein has emerged as a promising therapeutic target due to its multifaceted roles in various human diseases, with a primary focus on cancer. However, its implications extend beyond cancer,...

Read More


Unlocking Hope: DCAF5 as a Therapeutic Target for Rhabdoid Tumors and Beyond

Release Date: 13 July 2024

The exploration of innovative therapeutic strategies for cancer has taken an exciting turn with the recent identification of DCAF5 as a potential target in the treatment of rhabdoid tumors. These tumors, which are aggress...

Read More


Targeting cGAS for Precision Therapy in Autoimmune and Inflammatory Diseases

Release Date: 13 July 2024

The cyclic GMP-AMP synthase (cGAS) enzyme has emerged as a significant therapeutic target, with a major focus of research on autoimmune diseases and inflammatory conditions. The cGAS pathways plays a crucial role in the i...

Read More


Unleashing Immune Power: CEACAM1 as a Novel Cancer Immunotherapy Target

Release Date: 13 July 2024

CEACAM1, or Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1, has recently emerged as a novel immune checkpoint with significant potential as a cancer therapeutic target. This transmembrane glycoprotein plays a m...

Read More


Beqvez: Ushering in a New Era of Gene Therapy for Hemophilia B

Release Date: 13 July 2024

In a landmark announcement in late April 2024, Pfizer unveiled a pivotal advancement in hemophilia B treatment with the US FDA’s approval of Beqvezandtrade; (fidanacogene elaparvovec-dzkt). This groundbreaking gene ...

Read More


Unveiling BCL6: A Key Target in Lymphoma and Solid Tumor Therapeutics

Release Date: 13 July 2024

The B cell lymphoma 6 (BCL-6) protein serves as a key transcriptional repressor pivotal in governing gene expression throughout lymphocyte development and differentiation. Yet, its aberrant regulation has linked it to num...

Read More


1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 |

Need custom market research solution? We can help you with that too.